Recent developments include the announcement of Q3 2026 financial results and pipeline progress, detailed earnings call transcripts, and clinical data updates for ARCT-810 and ARCT-032 programs.

• Arcturus reported Q3 2026 financial results showing a net loss of $7.4 million and basic/diluted EPS of -$0.26 per share, with strong liquidity including $184.8 million in cash and equivalents as of September 30, 2026 [N1][S2].
• The company highlighted progress in its pipeline, including ongoing Phase 2 clinical trials for ARCT-810 (OTC deficiency) and ARCT-032 (cystic fibrosis), with interim data showing safety and tolerability [N1][N4].
• Commercial sales of the KOSTAIVE COVID-19 vaccine continue in Japan, with regulatory approvals in Europe and the UK validating the platform technology [N1].
• The Q3 2026 earnings call provided insights into clinical development plans, regulatory interactions, and manufacturing advancements [N2][N3].
• Arcturus unveiled next-generation OTC therapy platform data and emphasized its proprietary RNA delivery technologies as key differentiators [N8].

Arcturus has demonstrated platform validation through regulatory approvals and commercialization of its COVID-19 vaccine in multiple regions. Its proprietary technologies may enable differentiated RNA therapeutics with improved efficacy and safety profiles. The pipeline candidates for rare diseases such as OTC deficiency and cystic fibrosis address significant unmet medical needs with limited current treatment options. Ongoing clinical trials and planned studies provide milestones for potential advancement. The company's strong liquidity supports continued development and operational activities.

The company operates in a highly competitive and rapidly evolving RNA therapeutics landscape with scientific, regulatory, and commercial risks. Clinical development carries inherent uncertainties including safety, efficacy, and regulatory approval outcomes. The collaboration with CSL Seqirus has faced financial write-downs due to declining COVID-19 demand and regulatory challenges. The company reported net losses and negative earnings per share, reflecting ongoing investment and development costs. Market adoption and reimbursement for novel RNA therapeutics in rare diseases remain uncertain. Manufacturing scale-up and delivery challenges persist in RNA medicine development.

Arcturus Therapeutics' moat lies in its proprietary self-amplifying mRNA (STARR®) and lipid nanoparticle delivery (LUNAR®) platforms, which enable potentially more effective and durable RNA medicines at lower doses. The company's early regulatory approvals and commercialization of KOSTAIVE validate its technology. Its focus on rare diseases with high unmet needs and orphan drug designations provides regulatory incentives and potential market exclusivity. Partnerships with established vaccine developers like CSL Seqirus enhance commercialization capabilities. The combination of innovative technology, regulatory progress, and strategic partnerships contributes to its competitive positioning.

• Clinical Development Risk: Arcturus' RNA therapeutic candidates are in early to mid-stage clinical trials with inherent risks of failure due to safety, efficacy, or regulatory hurdles.
• Regulatory and Commercialization Risk: Regulatory approvals and market acceptance for novel RNA medicines, especially in rare diseases, are uncertain and may impact commercial success.
• Financial Risk: The company reported net losses and depends on continued financing and successful commercialization to sustain operations.
• Partnership Risk: The collaboration with CSL Seqirus has experienced a significant accounting write-down, reflecting challenges in the COVID-19 vaccine market and regulatory environment.
• Manufacturing and Delivery Risk: Scaling up manufacturing and ensuring safe, effective delivery of RNA medicines remain technical challenges that could affect product development and availability.

• Arcturus Therapeutics is a messenger RNA medicines company focused on developing therapeutics for liver and respiratory rare diseases, including ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF).
• The company developed the world's first approved self-amplifying mRNA (sa-mRNA) vaccine, KOSTAIVE®, approved in Japan, the EU, and the UK for COVID-19, with commercial sales starting in Japan in October 2024.
• Arcturus has proprietary platform technologies: STARR® (self-amplifying mRNA technology) and LUNAR® (lipid nanoparticle delivery system) designed to enhance immune response and delivery of RNA medicines.
• The internal pipeline includes RNA therapeutic candidates ARCT-810 for OTC deficiency and ARCT-032 for cystic fibrosis, both rare diseases with significant unmet medical needs.
• ARCT-032 is in Phase 2 clinical trials targeting CF patients with Class I CFTR mutations and those not benefiting from CFTR modulators; interim results showed safety and tolerability with some reductions in mucus burden.
• ARCT-810 is in Phase 2 trials for OTC deficiency, a rare genetic disorder causing ammonia accumulation; it has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from FDA and EMA.
• KOSTAIVE vaccine variants include ARCT-154 and updated versions targeting SARS-CoV-2 variants; manufacturing approvals include onshore and offshore production in Japan.
• The company partners with CSL Seqirus for development and commercialization of mRNA vaccines for COVID-19, influenza, and other infectious diseases.
• Financial snapshot as of 2026-09-30 shows cash and equivalents of $184.8 million, current assets of $189.4 million, current liabilities of $28.3 million, with strong liquidity ratios: current ratio 6.68 and cash ratio 6.52.
• Q3 2026 financial results reported a net loss of $7.4 million and basic/diluted EPS of -$0.26 per share.
• The company continues to advance platform technologies, early-stage research, manufacturing process development, and explores genome editing and new targeting approaches.
• The CF program is supported by the Cystic Fibrosis Foundation and focuses on restoring functional CFTR protein via inhaled mRNA therapy.
• The OTC program addresses a life-threatening metabolic disorder with no current cure except liver transplant, aiming to treat the underlying cause via mRNA therapy.
• Recent news includes Q3 2026 financial results and pipeline progress, earnings call transcripts, and clinical data highlights for ARCT-810 and ARCT-032.
• The company has regulatory approvals and commercial sales in Japan and Europe for its COVID-19 vaccine, validating its platform technology.
• The company disclosed a $430 million accounting write-down related to the CSL Seqirus collaboration due to declining COVID-19 burden and regulatory challenges.
• Safety data from clinical trials indicate ARCT-032 is generally safe and well tolerated with no serious adverse events linked to the drug.
• The company plans further clinical studies including a 12-week safety and efficacy study for ARCT-032 and a pediatric study for ARCT-810.
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.